NCT03270579 is a Phase 1 clinical trial of [18F]JNJ-64511070 in Healthy, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT03270579?

NCT03270579 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT03270579?

Interventions in NCT03270579: [18F]JNJ-64511070.

Is NCT03270579 still recruiting?

NCT03270579 is currently completed. Last updated 27 April 2025.

Last reviewed 2025-04-27 · How we verify

NCT03270579

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

Completed Phase 1 Last updated 27 April 2025

What this trial tests

Phase 1 trial testing [18F]JNJ-64511070 in Healthy in 8 participants. Completed in 6 February 2018.

Timeline

12 September 2017

Primary endpoint
6 February 2018

6 February 2018

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	8
Start date	12 September 2017
Primary completion	6 February 2018
Estimated completion	6 February 2018
Sites	1 location across Belgium

Drugs / interventions tested

[18F]JNJ-64511070 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of the study is to measure the whole-body distribution and radiation dosimetry of \[18F\]JNJ-64511070 in healthy male participants by positron emission tomography (PET) (Part A); and to measure the uptake, binding, distribution, and washout of \[18F\]JNJ-64511070 in the brain of healthy male participants by PET and to model tissue specific kinetics of \[18F\]JNJ-64511070 with the appropriate arterial input function (IF) (Part B).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dosimetry and kinetic modelling of [<sup>18</sup>F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain.
Koole M, Schmidt ME, Hijzen A, Cohilis M, et al · · 2025 · PMID 40694102 · DOI 10.1007/s00259-025-07428-3

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03270579 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 27 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03270579.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing